Cancer immunotherapy comes of age and looks for maturity

As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future.

Detalles Bibliográficos
Autores principales: Finck, Amanda, Gill, Saar I., June, Carl H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335079/
https://www.ncbi.nlm.nih.gov/pubmed/32620755
http://dx.doi.org/10.1038/s41467-020-17140-5
_version_ 1783554065341349888
author Finck, Amanda
Gill, Saar I.
June, Carl H.
author_facet Finck, Amanda
Gill, Saar I.
June, Carl H.
author_sort Finck, Amanda
collection PubMed
description As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future.
format Online
Article
Text
id pubmed-7335079
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73350792020-07-09 Cancer immunotherapy comes of age and looks for maturity Finck, Amanda Gill, Saar I. June, Carl H. Nat Commun Comment As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future. Nature Publishing Group UK 2020-07-03 /pmc/articles/PMC7335079/ /pubmed/32620755 http://dx.doi.org/10.1038/s41467-020-17140-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Comment
Finck, Amanda
Gill, Saar I.
June, Carl H.
Cancer immunotherapy comes of age and looks for maturity
title Cancer immunotherapy comes of age and looks for maturity
title_full Cancer immunotherapy comes of age and looks for maturity
title_fullStr Cancer immunotherapy comes of age and looks for maturity
title_full_unstemmed Cancer immunotherapy comes of age and looks for maturity
title_short Cancer immunotherapy comes of age and looks for maturity
title_sort cancer immunotherapy comes of age and looks for maturity
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335079/
https://www.ncbi.nlm.nih.gov/pubmed/32620755
http://dx.doi.org/10.1038/s41467-020-17140-5
work_keys_str_mv AT finckamanda cancerimmunotherapycomesofageandlooksformaturity
AT gillsaari cancerimmunotherapycomesofageandlooksformaturity
AT junecarlh cancerimmunotherapycomesofageandlooksformaturity

Ejemplares similares